EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. Zhu

SHANGHAI & SUZHOU, China–(BUSINESS WIRE)–EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Andrew X. Zhu, M.D., Ph.D., to the company�s Scientific Advisory Board. Dr. Zhu is internationally recognized as a leading authority in hepatocellular carcinoma and cholangiocarcinoma and brings decades of research and clinical expertise. He has served on the Advisory Boards of many biotech and pharma companies and is currently a Professor of Medicine at Harvard Medical School and Chief Scientific Officer at Jiahui Health.

“Dr. Zhu has an impressive track record of clinical expertise and innovation. He has designed, completed, and published a number of clinical studies and has developed novel strategies to treat liver and bile duct cancers, including exploring EGFR and MET inhibitors,” said Dr. Chengbin Wu, CEO and founder of EpimAb. “As an international expert and physician-scientist, Dr. Zhu will substantially contribute to our strategy as we advance EMB-01, EMB-02 and EMB-06 through clinical development and bring additional programs from our pipeline of bispecific antibodies into the clinic.”

“EpimAb has built a robust pipeline of clinical and preclinic bispecific antibodies based on its FIT-Ig platform, which combines the functions of two parental antibodies into a single molecule without the need for mutations, linkers, or other non-Ig components,” said Dr. Zhu. “I look forward to working with the EpimAb leadership team to help continue the advancement of the company’s novel clinical and preclinical stage bispecifics.”

Dr. Zhu received his M.D. from Beijing Medical University and his Ph.D. in microbiology from Columbia University. During his career, Dr. Zhu led pivotal studies of several drug candidates and combination therapies in development, resulting in regulatory approval and the identification of predictive and surrogate biomarkers. He has frequently served on the Advisory Boards of international pharmaceutical companies and is a founding member of the International Liver Cancer Association, a Fellow of the American College of Physicians, and a member of ASCO and AACR. Dr. Zhu has received numerous awards for his work, including the Translational Research Grant Award from the V Foundation for Cancer Research and the Jonathan Kraft Translational Award from the Massachusetts General Hospital Cancer Center.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit www.epimab.com.

Contacts

EpimAb Biotherapeutics

In the U.S.:

Dr. Stephan Lensky, COO/CBO

Direct: +1 978-870-6276

Stephan.lensky@epimab.com

In China:

Dr. David Gu, CFO

Direct: +86-21-61951011

IR@epimab.com
Dr. Jason Tang?BD Director

Direct: +86-21-61951014

yesheng.tang@epimab.com

Media Inquiries

MacDougall

Amanda Houlihan or Mario Brkulj

+1 781-235-3060 or +49 175 5711 562

epimab@macbiocom.com